The University of Queensland is set to take a second-generation molecular clamp vaccine to a proof-of-concept human trial.
Dr Melanie Saville, Executive Director of Vaccine R&D at CEPI, said the UQ team had demonstrated true grit and the power of the scientific process to yield tangible advances in vaccinology.
“The second-generation molecular clamp vaccine technology that UQ have developed could provide the world with an additional tool to rapidly respond to future pandemic threats.”
The clinical batch of the Clamp2 vaccine will be manufactured at the Queensland node of the National Biologics Facility (NBF) housed within UQ’s Australian Institute for Bioengineering and Nanotechnology.
Ben Hughes, Interim Director of NBF, said it was a significant achievement that a pivotal, proof-of-concept clinical trial would be conducted with material produced in Brisbane at UQ.
“This will be a Phase I trial to assess the safety and efficacy of the clamp2 platform in healthy volunteers,” Mr Hughes said.
Read the full article by UQ here.